This Week in JAMA: Huntington's Patients Can Safely Switch to Austedo Tablets
Results from the ARC-HD study were published, and showed that patients can easily switch from tetrabenazine to the recently approved Austedo.
Great-Granddaughter of Sigmund Freud To Give Poetry Reading for Huntington's Disease
Annie Freud, great-grandaughter of Sigmund, will be giving a poetry reading in an effort to raise funds for the Huntington's disease association.
Study Discovers New Gene Responsible for Huntington's Disease Progression
Per a British study published in Lancet Neurology, mutations of the MSH3 gene may be associated with Huntington's disease (HD) progression.
Triple Threat: HD Patient Researches, Educates and Advocates
He's a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
IONIS-HTT Rx Study in HD Patients Completes Enrollment
Ionis the completion of enrollment in its Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRs in Huntington's Disease patients.
Is ECT a Good Treatment Option for Huntington's Disease Patients?
Crowd of 1,700 Comforted by Pope Francis' Comments on HD
On May 18, Pope Francis embraced 150 Huntington's disease patients. The meeting was the first time a world leader recognized HD.
Pope to Meet with Huntington's Disease Patients on Thursday
On Thursday, Pope Francis will become the first world leader to recognize the growing global burden that is Huntington's Disease (HD).
Pope Francis to Pray with Huntington's Disease Families
The Papal audience will hopefully shine a spotlight on a disease that often remains hidden from the outside world.
FDA Approves Drug for Huntington's Disease
The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease. The drug has previously been referred to as SD-809 by its developers, Teva Pharmaceuticals.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.